Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists in Private Practice in the U.S.

June 5, 2007
Melafind
By a GLG Expert Contributor
Analysis of: Digital Diagnosis: New Tool for Detecting Skin Cancer (www.ehponline.org)
Depending on the accuracy and cost of the technology, this device could be a useful and welcome tool in melanoma diagnosis.  To be considered useful, the Melafind device must increase melanoma recognition without a significant false negative rate.  In other words, the machines ability to catch...
May 3, 2007
Timing is everything here.
By a GLG Expert Contributor
Analysis of: Pharmacyclics Announces FDA Filing of New Drug Application for Xcytrin(R) Injection to Treat Lung Cancer Brain Metastases (www.pipelinereview.com)
Xcytrin (motexafin gadolinium) is a rationally designed compound that concentrates selectively in cancer cells, inducing redox stress and triggering apoptosis (cell suicide). Xcytrin has been shown to be synergistic with radiation and in the pivotal phase III SMART trial was shown to improve the...
May 3, 2007
New therapy for rare tumor
By a GLG Expert Contributor
Analysis of: Positive Results Prompt US National Cancer Institute To Make Gleevec(R) Available To Patients In Post-Surgical GIST Study (www.medicalnewstoday.com)
The primary end point of the phase III trial "Imatinib Mesylate (Gleevec) in Treating Patients with Primary GIST that has been Completely Removed by Surgery" was recurrence free survival with the secondary endpoints of overall survival, efficacy, and safety. The study was closed early with the announcement...
February 15, 2007
Nexavar---- king of the rare tumors
By a GLG Expert Contributor
Analysis of: Bayer to File for Nexavar Approval for Liver Cancer (www.therapeuticsdaily.com)
Nexavar continues to expand its place in the oncology arena.Nexavar is approved for renal cell ca and I suspect hepatocellular approval is not far behind.
February 12, 2007
UNCERTAINTY IN PHASE II TRIALS
By a GLG Expert Contributor
Analysis of: Study Finds Flaws in Cancer Clinical Trials (pharmalive.com)
The authors once more underline the known limitations of phase II studies, originating from their uncontrolled design and limited statistical power. The proposed remedies will result in only minor improvements.

Previous Page : 1 2 3 4 5 651 to 55 of 55

Analytics


Generated at 2009-01-07T19:00:58.307